Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3

Roche is moving its next-generation hemophilia A treatment into Phase 3 testing next year after seeing the early-stage data. The pharma disclosed Monday that part of the Phase 3 program will ...